{"entity":{"id":"andrew-lassman","kind":"person","name":"Andrew B. Lassman","aka":[],"tldr":"New York neuro-oncologist who led INTELLANCE-1, the trial that tested the EGFR-directed antibody-drug conjugate depatuxizumab mafodotin in newly diagnosed glioblastoma and found it did not extend survival.","summary":"Andrew Lassman is chief of neuro-oncology at Columbia University Irving Medical Center. He was the lead investigator and first author of the 2023 Neuro-Oncology report of INTELLANCE-1, the phase 3 trial of depatuxizumab mafodotin added to radiotherapy and temozolomide in EGFR-amplified newly diagnosed glioblastoma, which showed no overall survival benefit despite earlier promise. He leads several cooperative-group glioma trials.","asOf":"2026-09-18","links":[],"tags":["brain","trialist"],"related":[],"cancers":["glioblastoma","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["columbia-hicc"],"pathways":[],"terms":[],"trials":["intellance-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Chief of Neuro-Oncology, Columbia University Irving Medical Center","institutionId":"columbia-hicc","specialisms":["Glioblastoma","Antibody-drug conjugates","Neuro-oncology trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lassman%5BAuthor%5D"}],"papers":[],"orcid":"0000-0001-7386-9928"},"route":"/people/andrew-lassman/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"institution":[{"id":"columbia-hicc","kind":"institution","name":"Herbert Irving Comprehensive Cancer Center, Columbia University","route":"/institutions/columbia-hicc/"}],"trial":[{"id":"intellance-1","kind":"trial","name":"INTELLANCE-1","route":"/trials/intellance-1/"}]}}